273 related articles for article (PubMed ID: 23808960)
1. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability.
Montgomery S; Emir B; Haswell H; Prieto R
Curr Med Res Opin; 2013 Oct; 29(10):1223-30. PubMed ID: 23808960
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.
Feltner DE; Crockatt JG; Dubovsky SJ; Cohn CK; Shrivastava RK; Targum SD; Liu-Dumaw M; Carter CM; Pande AC
J Clin Psychopharmacol; 2003 Jun; 23(3):240-9. PubMed ID: 12826986
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of pregabalin in generalized anxiety disorder.
Feltner D; Wittchen HU; Kavoussi R; Brock J; Baldinetti F; Pande AC
Int Clin Psychopharmacol; 2008 Jan; 23(1):18-28. PubMed ID: 18090504
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
5. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy.
Beydoun A; Uthman BM; Kugler AR; Greiner MJ; Knapp LE; Garofalo EA;
Neurology; 2005 Feb; 64(3):475-80. PubMed ID: 15699378
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.
Feltner DE; Liu-Dumaw M; Schweizer E; Bielski R
Int Clin Psychopharmacol; 2011 Jul; 26(4):213-20. PubMed ID: 21368587
[TBL] [Abstract][Full Text] [Related]
8. Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials.
Uthman BM; Bazil CW; Beydoun A; Schulze-Bonhage A; Benabou R; Whalen E; Emir B; Griesing T; Leon T
Epilepsia; 2010 Jun; 51(6):968-78. PubMed ID: 20345940
[TBL] [Abstract][Full Text] [Related]
9. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
Baldwin DS; Schweizer E; Xu Y; Lyndon G
Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
[TBL] [Abstract][Full Text] [Related]
10. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.
Kasper S; Brasser M; Schweizer E; Lyndon G; Prieto R
Eur Neuropsychopharmacol; 2014 Jan; 24(1):125-32. PubMed ID: 24290532
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China.
Guan Y; Ding X; Cheng Y; Fan D; Tan L; Wang Y; Zhao Z; Hong Z; Zhou D; Pan X; Chen S; Martin A; Tang H; Cui L
Clin Ther; 2011 Feb; 33(2):159-66. PubMed ID: 21444113
[TBL] [Abstract][Full Text] [Related]
13. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Tassone DM; Boyce E; Guyer J; Nuzum D
Clin Ther; 2007 Jan; 29(1):26-48. PubMed ID: 17379045
[TBL] [Abstract][Full Text] [Related]
14. Pregabalin for the treatment of generalized anxiety disorder.
Wensel TM; Powe KW; Cates ME
Ann Pharmacother; 2012 Mar; 46(3):424-9. PubMed ID: 22395254
[TBL] [Abstract][Full Text] [Related]
15. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
16. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.
Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H
Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study.
Greist JH; Liu-Dumaw M; Schweizer E; Feltner D
Int Clin Psychopharmacol; 2011 Sep; 26(5):243-51. PubMed ID: 21734588
[TBL] [Abstract][Full Text] [Related]
18. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
19. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia.
Arnold LM; Emir B; Murphy TK; Zeiher BG; Pauer L; Scott G; Petersel D
Clin Ther; 2012 May; 34(5):1092-102. PubMed ID: 22503162
[TBL] [Abstract][Full Text] [Related]
20. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention.
Bandelow B; Wedekind D; Leon T
Expert Rev Neurother; 2007 Jul; 7(7):769-81. PubMed ID: 17610384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
